After infections and other inflammatory agents that could have produced his symptoms had been excluded captopril was stopped. The concomitant drugs remained unchanged. He improved rapidly within five days, the pleural effusions regressed, and signs ofpericarditis disappeared. His C reactive protein concentration, which was raised on admission .at 7-7 g/l (normal <0 5 g/l), fell to 2-7 g/l one week later and to a normal value three months later. Simultaneously the increased activities of liver enzymes returned to normal. After he stopped captopril no signs of recurrence were observed.
In view of previous evidence of lupoid skin and haematological changes induced by captopril, the clinical history of this patient, who rapidly improved after stopping this angiotensin converting enzyme inhibitor, is suggestive of a drug induced systemic lupus erythematosus syndrome, although there were no antibodies to DNA-a common finding in drug induced lupus.' She was treated with fresh frozen plasma. The bleeding stopped and did not recur. Her international normalised ratio returned to 2-4 over the course of two days, at which point warfarin was started. She was subsequently restabilised at her previous dose.
Itraconazole probably potentiated the effect of warfarin. Fluconazole, also a triazole antifungal drug, is known to enhance the effects of warfarin (Pfizer, personal communication) . In premarketing studies itraconazole was not shown to affect the protein binding of warfarin (technical brochure on Sporanox, April 1989, Janssen). The mechanism of interaction between itraconazole and warfarin remains unclear.
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